Whilst the field of T-cell engineering is in its infancy, many exciting advances were presented at the International Conference on Lymphocyte Engineering (ICLE) 2022. Michael Traxlmayr, PhD, University of Natural Resources and Life Sciences, Vienna, Austria, comments on some of his highlights during the conference, including engineering Foxp3+ regulatory T (Treg) cells, which will potentially expand the utility of T-cell therapies. This interview took place at ICLE 2022.